TABLE 1.
Baseline characteristics of subjects in the INBUILD and INPULSIS trials
| Characteristic | INBUILD trial (overall population) | INPULSIS trials (pooled) | ||
| Nintedanib (n=332) | Placebo (n=331) | Nintedanib (n=638) | Placebo (n=423) | |
| Male sex | 179 (53.9) | 177 (53.5) | 507 (79.5) | 334 (79.0) |
| Age years | 65.2±9.7 | 66.3±9.8 | 66.6±8.1 | 67.0±7.9 |
| Former or current smoker | 169 (50.9) | 169 (51.1) | 464 (72.7) | 301 (71.2) |
| FVC mL | 2340±740 | 2321±728 | 2714±757 | 2728±810 |
| FVC % predicted | 68.7±16.0 | 69.3±15.2 | 79.7±17.6 | 79.3±18.2 |
| DLCO# % predicted | 44.4±11.9 | 47.9±15.0 | 47.4±13.5 | 47.0±13.4 |
Data are presented as n (%) or mean±sd. DLCO: diffusing capacity of the lung for carbon monoxide; FVC: forced vital capacity. #: corrected for haemoglobin level.